Flecainide-Induced Interstitial Lung Disease: A Case Report and Review of the Literature

This case describes a rare adverse effect in which the subject developed interstitial lung disease after initiating a class IC antiarrhythmic, flecainide. There is no current treatment recommendation for flecainide-induced interstitial lung disease. Previously reported cases were successful with discontinuation of the offending drug and initiation of systemic corticosteroids; however, this patient did not respond to this treatment plan, resulting in death. Obtaining a thorough patient history regarding new medications and the start of symptoms played a crucial role when creating a differential diagnosis for this case.